ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 55.4 | 39.8 | 14.0 |
| Other income | 1.0 | 1.0 | 0.9 |
| Total income | 56.4 | 40.8 | 14.9 |
| Profit before exceptional items & tax | 1.9 | -1.3 | -0.4 |
| Profit before tax | 1.9 | -1.3 | -0.4 |
| Net profit | 1.4 | -0.8 | -0.3 |
| Operating margin | 3.4% | -3.2% | -2.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +295.70% |
|---|
BSE results filing, NSE: ADIRASA. Figures extracted from the filing.
Genpharmasec Ltd: key numbers
- Share price
- ₹1.14
- Market cap
- ₹63.12 Cr
- Revenue (annual)
- ₹139.9 Cr
- Net profit (annual)
- ₹1.60 Cr
- P/E (TTM)
- 27.4×Sector 43.8×
- Promoter holding
- 32.06%+2.08% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Genpharmasec Ltd
All →Genpharmasec Management Change
Genpharmasec's Company Secretary and Compliance Officer Hardik Makwana resigned, effective 16 November 2026. The resignation reflects a senior key managerial personnel departure, citing other professional opportunities.
Genpharmasec Financial Results
Genpharmasec approved unaudited half-year results and planned sale of its wholly owned subsidiary Clinigenome India. Company Secretary Hardik Makwana resigns effective 16 November 2026.
Genpharmasec Board Meeting Date
Genpharmasec Ltd will hold a Board meeting on 03 Nov 2026. Agenda includes proposing approval of Q2/H1 FY27 unaudited results.
Genpharmasec Other Announcement
Genpharmasec Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing provides a standard breakdown of promoter and public shareholding.
Genpharmasec Annual General Meeting
Genpharmasec Limited conducted its 34th Annual General Meeting on September 29, 2026. Shareholders considered resolutions including the adoption of FY26 financial statements and director re-appointments.
Genpharmasec Annual Report
Genpharmasec Ltd filed its 34th Annual Report for FY 2025-26 with BSE, including the AGM notice for 29 September 2026. The report covers audited financials, board updates, and governance disclosures.